Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Cidara Therapeutics (CDTX) and adjusts the price target to $25 from $3.

April 25, 2024 | 6:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham maintains a Buy rating on Cidara Therapeutics, significantly raising the price target from $3 to $25.
The substantial increase in the price target by a reputable analyst firm like Needham suggests a strong bullish outlook for Cidara Therapeutics. This adjustment reflects a significant positive reassessment of the company's value and prospects, likely based on recent developments or anticipated future performance. Such a dramatic change can positively influence investor sentiment and potentially lead to a short-term increase in stock price as the market adjusts to the new valuation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100